Suppression of hypoxia-induced HIF-1α accumulation by VEGFR inhibitors: Different profiles of AAL993 versus SU5416 and KRN633

被引:35
作者
Ban, Hyun Seung [1 ]
Uno, Masaharu [1 ]
Nakamura, Hiroyuki [1 ]
机构
[1] Gakushuin Univ, Fac Sci, Dept Chem, Tokyo 1718588, Japan
关键词
AAL993; SU5416; KRN633; Hypoxia-inducible factor; Vascular endothelial growth factor inhibitor; ENDOTHELIAL GROWTH-FACTOR; INDUCIBLE FACTOR 1-ALPHA; KINASE INHIBITORS; TYROSINE KINASES; PROLINE HYDROXYLATION; GENE-EXPRESSION; FACTOR RECEPTOR; HIF-ALPHA; PATHWAY; ANGIOGENESIS;
D O I
10.1016/j.canlet.2010.03.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The hypoxia-inducible factor (HIF) is a heterodimeric basic helix-loop-helix transcriptional factor and the activated HIF plays pivotal roles in various pathological conditions, including inflammation and cancer. HIF-1 alpha overexpression has been observed in many common human cancers, including brain, breast, colon, lung, ovary, and prostate, and HIF-mediated genes, such as vascular endothelial growth factor (VEGF), inducible nitric oxide synthase (iNOS), and insulin-like growth factor (IGF)-1, are associated with tumor angiogenesis, metastasis, and invasion. Therefore, the pro-oncogenic protein HIF is a novel target of cancer therapy. We examined the effects of VEGFR inhibitors, AAL993, SU5416, and KRN633, on suppression of HIF-l alpha accumulation under the hypoxic condition. We found that VEGFR tyrosine kinase inhibitors, AAL993, SU5416, and KRN633, possess dual functions: inhibition of VEGFR signaling and HIF-1 alpha expression under the hypoxic condition. The detailed mechanistic study indicated that SU5416 and KRN633 suppressed HIF-1 alpha expression through inhibition of both Akt and ERK phosphorylation signaling pathways, whereas AAL993 suppressed HIF-1 alpha expression through ERK inhibition without affecting Akt phosphorylation. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:17 / 26
页数:10
相关论文
共 46 条
[1]  
Banerjee D, 2001, ANTICANCER RES, V21, P3941
[2]   HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1α degradation [J].
Berra, E ;
Richard, DE ;
Gothié, E ;
Pouysségur, J .
FEBS LETTERS, 2001, 491 (1-2) :85-90
[3]   Vascular endothelial growth factor C induces angiogenesis in vivo [J].
Cao, YH ;
Linden, P ;
Farnebo, J ;
Cao, RH ;
Eriksson, A ;
Kumar, V ;
Qi, JH ;
Claesson-Welsh, L ;
Alitalo, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (24) :14389-14394
[4]   Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein [J].
Cockman, ME ;
Masson, N ;
Mole, DR ;
Jaakkola, P ;
Chang, GW ;
Clifford, SC ;
Maher, ER ;
Pugh, CW ;
Ratcliffe, PJ ;
Maxwell, PH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (33) :25733-25741
[5]   HIF-1α is essential for myeloid cell-mediated inflammation [J].
Cramer, T ;
Yamanishi, Y ;
Clausen, BE ;
Förster, I ;
Pawlinski, R ;
Mackman, N ;
Haase, VH ;
Jaenisch, R ;
Corr, M ;
Nizet, V ;
Firestein, GS ;
Gerber, HP ;
Ferrara, N ;
Johnson, RS .
CELL, 2003, 112 (05) :645-657
[6]   Induction of hypoxia-inducible factor 1α gene expression by vascular endothelial growth factor [J].
Deudero, Juan Jose P. ;
Caramelo, Carlos ;
Castellanos, Maria Carmen ;
Neria, Fernando ;
Fernandez-Sanchez, Ruth ;
Calabia, Olalla ;
Penate, Silvia ;
Gonzalez-Pacheco, Francisco Roman .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (17) :11435-11444
[7]   Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: correlation with clinical features [J].
Feng, CW ;
Wang, LD ;
Jiao, LH ;
Liu, B ;
Zheng, S ;
Xie, XJ .
BMC CANCER, 2002, 2 (1)
[8]   Epigenetic consequences of AML1-ETO action at the human c-FMS locus [J].
Follows, GA ;
Tagoh, H ;
Lefevre, P ;
Hodge, D ;
Morgan, GJ ;
Bonifer, C .
EMBO JOURNAL, 2003, 22 (11) :2798-2809
[9]   Astrocyte apoptosis induced by HIV-1 transactivation of the c-kit protooncogene [J].
He, JL ;
deCastro, CM ;
Vandenbark, GR ;
Busciglio, J ;
Gabuzda, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (08) :3954-3959
[10]   Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis [J].
Herbst, Roy S. ;
Heymach, John V. ;
O'Reilly, Michael S. ;
Onn, Amir ;
Ryan, Anderson J. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (02) :239-249